United Capital Financial Advisors LLC Raises Stock Position in Edwards Lifesciences Co. (NYSE:EW)

United Capital Financial Advisors LLC lifted its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 64.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,859 shares of the medical research company's stock after buying an additional 9,779 shares during the period. United Capital Financial Advisors LLC's holdings in Edwards Lifesciences were worth $1,840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of EW. Vanguard Group Inc. increased its position in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP raised its stake in Edwards Lifesciences by 5.3% during the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after acquiring an additional 1,678,154 shares during the period. Geode Capital Management LLC boosted its position in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock worth $1,007,520,000 after purchasing an additional 126,194 shares during the period. Fisher Asset Management LLC increased its stake in shares of Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock worth $723,664,000 after purchasing an additional 696,965 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $610,895,000. Institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

EW has been the subject of a number of analyst reports. Truist Financial cut their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Evercore ISI cut their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. Finally, Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $78.55.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,853 shares of company stock worth $5,163,062. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Down 3.2 %

NYSE:EW traded down $2.30 during mid-day trading on Monday, hitting $69.23. 3,767,362 shares of the company's stock traded hands, compared to its average volume of 4,926,556. The company has a fifty day moving average of $71.18 and a 200 day moving average of $70.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a market capitalization of $40.70 billion, a P/E ratio of 9.93, a P/E/G ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.